Beck Mack & Oliver’s Verrica Pharmaceuticals VRCA Stock Holding History

Beck Mack & Oliver’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.4K	Hold	12,000	–	–	﹤0.01%	196
2026 Q1	$63.5K	Hold	12,000	–	–	﹤0.01%	192
2025 Q4	$99.7K	Buy	+12,000	New	+$66.5K	﹤0.01%	188
2025 Q3	–	Sell	-7,000	Closed	-$37.1K	–	193
2025 Q2	$37.1K	Hold	7,000	–	–	﹤0.01%	183
2025 Q1	$31K	Hold	7,000	–	–	﹤0.01%	182
2024 Q4	$49K	Hold	7,000	–	–	﹤0.01%	183
2024 Q3	$102K	Buy	7,000 +4,000	+133%	+$180K	﹤0.01%	170
2024 Q2	$219K	Hold	3,000	–	–	﹤0.01%	164
2024 Q1	$178K	Hold	3,000	–	–	﹤0.01%	169
2023 Q4	$220K	Hold	3,000	–	–	0.01%	168
2023 Q3	$117K	Hold	3,000	–	–	﹤0.01%	161
2023 Q2	$173K	Hold	3,000	–	–	﹤0.01%	166
2023 Q1	$195K	Hold	3,000	–	–	0.01%	162
2022 Q4	$82.5K	Hold	3,000	–	–	﹤0.01%	168
2022 Q3	$88K	Hold	3,000	–	–	﹤0.01%	164
2022 Q2	$58K	Buy	3,000 +2,000	+200%	+$101K	﹤0.01%	169
2022 Q1	$81K	Hold	1,000	–	–	﹤0.01%	187
2021 Q4	$92K	Hold	1,000	–	–	﹤0.01%	200
2021 Q3	$125K	Hold	1,000	–	–	﹤0.01%	210
2021 Q2	$113K	Hold	1,000	–	–	﹤0.01%	198
2021 Q1	$152K	Hold	1,000	–	–	﹤0.01%	184
2020 Q4	$115K	Hold	1,000	–	–	﹤0.01%	193
2020 Q3	$77K	Hold	1,000	–	–	﹤0.01%	187
2020 Q2	$110K	Hold	1,000	–	–	﹤0.01%	186
2020 Q1	$109K	Hold	1,000	–	–	﹤0.01%	178
2019 Q4	$159K	Hold	1,000	–	–	0.01%	207
2019 Q3	$148K	Hold	1,000	–	–	0.01%	201
2019 Q2	$116K	Hold	1,000	–	–	﹤0.01%	213
2019 Q1	$108K	Hold	1,000	–	–	﹤0.01%	214
2018 Q4	$82K	Buy	+1,000	New	+$121K	﹤0.01%	212

Other funds holding VRCA

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Beck Mack & Oliver's VRCA Position: Q2 2026 in Review

Beck Mack & Oliver held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 12,000 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #196.

Beck Mack & Oliver first reported a position in VRCA in Q4 2018 and has held it in 30 quarters since. The position peaked at $220K in Q4 2023. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

Beck Mack & Oliver held 12,000 shares of Verrica Pharmaceuticals worth $73.4K as of Q2 2026.
Beck Mack & Oliver left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
Verrica Pharmaceuticals made up ﹤0.01% of Beck Mack & Oliver's portfolio in Q2 2026, its #196 holding.
Beck Mack & Oliver first reported a position in Verrica Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
Beck Mack & Oliver's Verrica Pharmaceuticals position peaked at $220K in Q4 2023.
43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Beck Mack & Oliver's 13F filing for Q2 2026, filed 14 Aug 2026.